Friday, 14 Jun 2019

You are here

The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)

Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.

  1. European Commission has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of adults with active psoriatic arthritis (PsA) with an inadequate response to DMARDs https://t.co/G6YYXSuUyQ
  2. Study of 14 EGPA pts shows mean age 12.3 yrs, All w/ Lung, upper airway (85%), skin (71%), GI tract (64%), heart (57%). CNS & renal Dz were rare. Only 31% ANCA+. Compared to adult, kids have more ENT, CV, & GI. https://t.co/v1wwrTUgsT 
  3. MPO (myeloperoxidase) Abs(MPO-ANCA, pANCA) may be associated with a wider variety - GPA, EGPA, microscopic polyangiitis, Goodpastures, PAN, glomerulonephritis, lupus, interstitial lung dz, bronchiectasis, alveolar hemorrhage, RA, IBD, autoimmune liver dz https://t.co/cWb0UeOu0h 
  4. TMP/SMX prophylaxis following rituximab in ANCA+ associated vasculitis reduces infections by 70% (HR 0.30) - 192 AAV pts with 92 infx in 49 pts (only 1 due to PJP). https://t.co/VmVDXQqlSZ 
  5. Taiwan claims analysis of #RA patients shows that despite low rates (10-20%) of influenza vaccination, those vaccinated had a significant ~35% lower rate of death and hospitalization (sepsis, bacteremia, viremia) https://t.co/Y17d66AZnC
  6. HCQ use in Lupus associated with 32% lower risk of all cause mortality at 1 yr. (a Taiwan claims data study of 2287 #SLE patients either on or off plaquenil) https://t.co/qt4nFcYCQw
  7. The risk of psoriatic arthritis in psoriasis is 23.8% according to a systematic review and metanalysis in JAAD (using CASPAR criteria). The incidence of PsA in psoriasis ranged from 0.27-2.7/100PY https://t.co/tnw41vFQe3   
  8. Study of 20,000+ patients receiving knee or hip replacements finds that, compared to OA, #RA patients have a high risk of post-op MI (HZ 3.54) and more revision surgeries (HZ 1.61)over 10 yrs https://t.co/YXH5FqHnr0 
  9. Public Citizen Pressures FDA to Pull Febuxostat   
  10. Ixekizumab Effective in Ankylosing Spondylitis 
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.

1. Genovese Vagal nerve stimulator in RA

2. Low dose steroids in Hand OA

EULAR 2019 Report – Day 2

It was a full and lively 2nd day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid 

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed.